Short Course Radiation Therapy in Palliative Treatment of Complicated Bone Metastases
NCT ID: NCT03503682
Last Updated: 2018-04-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
82 participants
INTERVENTIONAL
2017-11-08
2023-11-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Short Course Radiotherapy in Complicated Bone Metastases Palliation
NCT03455231
Short Course Radiation Therapy in Palliative Treatment of Brain Metastases
NCT03525301
Short Course Radiation Therapy in Palliative Treatment of Head and Neck Cancer
NCT03804073
Short Course Radiation Therapy in Palliative Treatment of Abdominal Cancer
NCT03775005
Short Course Radiation Therapy in Palliative Treatment of Pelvic Cancer
NCT03804333
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
standard treatment
Patients in this group are treated with 3000 cGy in 10 daily fractions
standard treatment
3000 cGy in 10 daily fractions
short course treatment
Patients in this group are treated with 2000 cGy in 4 fractions administered twice a day (at least 6-8 hours interval)
short course treatment
2000 cGy in 4 fractions administered twice a day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
standard treatment
3000 cGy in 10 daily fractions
short course treatment
2000 cGy in 4 fractions administered twice a day
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* age \>18 years
* ECOG performance status 0-3
* symptomatic lesion (NRS \>1)
* no changes in analgesic treatment at least in the week before radiotherapy
Exclusion Criteria
* previously irradiation of the same region
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
IRCCS Azienda Ospedaliero-Universitaria di Bologna
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Alessio Giuseppe Morganti
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alessio G Morganti, MD
Role: PRINCIPAL_INVESTIGATOR
Radiation Oncology Center, Department of Experimental, Diagnostic and Speciality Medicine-DIMES, Unversity of Bologna, S. Orsola-Malpighi Hospital, Bologna, Italy
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Radiation Oncology Center, Department of Experimental, Diagnostic and Speciality Medicine- DIMES, University of Bologna, S.Orsola-Malpighi Hospital
Bologna, BO, Italy
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Zamagni A, Siepe G, Gibertoni D, Donati CM, Cellini F, Fiorica F, Pezzulla D, Deodato F, Candoli F, Bisello S, Scirocco E, Manfrida S, Gabbani M, Cilla S, Macchia G, Morganti AG. Accelerated Radiotherapy for Complicated Bone Metastases: SHARON Bone Randomized Phase III Trial Shows Non-Inferiority Compared to Standard Palliative Fractionation (NCT03503682). Cancers (Basel). 2025 Jun 16;17(12):2000. doi: 10.3390/cancers17122000.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RT-15-06 SHARON BONE
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.